Literature DB >> 2164165

[Ependymoma of the intradural filum terminale in adults. 20 cases].

M Rivierez1, S Oueslati, J Philippon, P Pradat, J F Foncin, B Muckensturm, D Dorwling-Carter, P Cornu.   

Abstract

Twenty cases of ependymomas of the intradural filum terminale in adults have been reviewed. Their pathology was quite uniform, of a myxopapillary type, similar to the low grade ependymoma described by Kernohan, which represent about 23% of the tumours of cauda equina. Mean age of the patients was 35.7 years. Mean time between the first symptom and the diagnosis was 46 months. Clinical symptoms were often non specific, with low back pain and radiculalgias. At the time of operation, clinical signs were essentially motor deficits usually moderate (11 cases), sphincter disturbances (10 cases), and sensory loss (9 cases). In 3 patients with rapid worsening, an intratumoral haemorrhage was found. In 2 other cases, intracranial hypertension was the main symptom: in the first, it was related to hydrocephalus probably caused by spinal subarachnoid haemorrhage; in the second, there was no ventricular dilatation. In this series, neuroradiological examinations had consisted mainly in myelographies. C.T. scan has been performed in 3 patients; in only one case it has allowed to visualize a presacral extension. One patient had preoperative M.R.I.: the association of an expansive lesion with upper cyst in conus medullaris and presence of blood in the sacral area permitted the diagnosis of ependymoma of the filum terminalis. The average size of the tumours was 8 cm. Total removal has been possible in 15 cases (and in 2 of the 5 giant tumours), subtotal removal in 2 cases, and partial removal in 3 cases. In 4 patients where existed an intraspinal cord extension above the conus, it has been resected completely, except for one case with recurrence. Patients with a total removal had a good functional recovery (13/15). No recurrence has been observed in this group. In conclusion, with M.R.I., one may hope an earlier diagnosis, condition of radical surgery. So, radiotherapy which is not without risk, could be avoided.

Entities:  

Mesh:

Year:  1990        PMID: 2164165

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  7 in total

1.  Recurrence from filum terminale ependymoma 42 years after 'total' removal and radiotherapy.

Authors:  P Celli; L Cervoni; M Salvati; G Cantore
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Ependymoma of the filum terminale: treatment and prognostic factors in a series of 28 cases.

Authors:  P Celli; L Cervoni; G Cantore
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

3.  Long term outcomes following surgical resection of myxopapillary ependymomas.

Authors:  Carlos A Bagley; Sean Wilson; Karl F Kothbauer; Markus J Bookland; Fred Epstein; George I Jallo
Journal:  Neurosurg Rev       Date:  2009-02-17       Impact factor: 3.042

4.  Acute neurological deterioration as a result of two synchronous hemorrhagic spinal ependymomas.

Authors:  Rafael Martinez-Perez; Aurelio Hernandez-Lain; Igor Paredes; Pablo M Munarriz; Ana M Castaño-Leon; Alfonso Lagares
Journal:  Surg Neurol Int       Date:  2012-03-14

5.  Spontaneous Hemorrhage of a Spinal Ependymoma in the Filum Terminale Presenting with Acute Cauda Equina Syndrome: Case Report.

Authors:  Tohru Terao; Naoki Kato; Takuya Ishii; Keisuke Hatano; Hideaki Takeishi; Shota Kakizaki; Satoshi Tani; Yuichi Murayama
Journal:  NMC Case Rep J       Date:  2016-05-16

6.  Extramedullary Conus Ependymoma Involving a Lumbar Nerve Root with Filum Terminale Attachment.

Authors:  Takashi Moriwaki; Koichi Iwatsuki; Yu-Ichiro Ohnishi; Koshi Ninomiya; Toshiki Yoshimine
Journal:  Clin Med Insights Case Rep       Date:  2015-11-30

7.  Acute Paraplegia as a Result of Hemorrhagic Spinal Ependymoma Masked by Spinal Anesthesia: Case Report and Review of Literature.

Authors:  Sang-Hyo Lee; David Jaehyun Park; Sin-Soo Jeun
Journal:  Brain Tumor Res Treat       Date:  2016-04-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.